MetaCap

ProKidney Corp. Class A (PROK)

NASDAQ: PROKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.04-0.02 (-1.89%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PROK stock chart

Technical analysis

Key statistics

All statistics
Market cap
$415.21M
EPS (TTM)
-$0.61
52-week range
0.87 – 2.65
Day range
1.02 – 1.08
Volume / Avg
1.90M / 1.44M
Beta
—

52-week range

$0.87$2.65

PROK stock today

Shares of ProKidney (PROK) finished lower on Nov 20 at $1.04, a drop of 1.89% or $0.02 per share, versus the S&P 500's 3.70% decline. At this level, PROK sits near the bottom of its 52-week range of $0.87 to $2.65: 60.8% below the high, set on Dec 5, 2025 and 19.5% above the low. PROK is down 53.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 52.5%.

ProKidney has posted a net loss over the last twelve months (EPS of -$0.61), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About ProKidney

Company profile

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Bruce Culleton M.D.
Headquarters
Winston-Salem, NC
Employees
231
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, ProKidney generated $893,000 in revenue, up 1075.0% from fiscal 2024, its 2nd consecutive year of revenue growth. ProKidney reported a net loss of $69.0 million, compared with a loss of $61.2 million a year earlier. Operating margin was -18477.8%.

ProKidney annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$893.00K$76.00K$0$0—
Growth+1075.00%————
Net income$-68.99M$-61.19M$-35.47M$-148.13M$-55.15M
EPS (diluted)———$-0.23—

Analyst forecast

Forecast

Consensus (6 analysts)

buy

Avg. price target

$6.50+525.00%

  • Strong buy 0
  • Buy 4
  • Hold 1
  • Sell 0
  • Strong sell 1

Target range

Low $1.00High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.17 vs $-0.13
Surprise
-30.77%

PROK news

All PROK news

ProKidney peers

Health Care sector
PROK peer companies
CompanyPrice% ChgMarket capCompare
TECXTectonic Therapeutic Inc.20.73-1.47%$405.26Mvs PROK
TVGNTevogen Inc.5.90-6.35%$405.20Mvs PROK
IRLAIRulya Therapeutics Inc.39.88-0.15%$432.36Mvs PROK
CADLCandel Therapeutics Inc.5.04-1.75%$395.37Mvs PROK
FENCFennec Pharmaceuticals Inc.13.09-2.68%$462.14Mvs PROK
RGNXREGENXBIO Inc.7.16-0.28%$473.44Mvs PROK
SANASana Biotechnology Inc.1.59-8.62%$476.42Mvs PROK
ALECAlector Inc.2.34+1.52%$347.63Mvs PROK

Indexes, lists and sector

ProKidney stock FAQ

What is ProKidney's stock price today?

PROK last traded at $1.04 as of Nov 20, 4:00 PM EST, down 1.89% on the day. Prices are delayed at least 15 minutes.

Who is ProKidney's CEO?

Dr. Bruce Culleton M.D. is the chief executive officer of ProKidney Corp. Class A, which has about 231 employees.

What is the PROK 52-week high?

The 52-week high for PROK is $2.65 and the 52-week low is $0.87. The stock is currently 60.8% below its high.

Compare PROK